Table 1 The list of merged SE regions in LUAD cases from the National Cancer Center Japan cohort
From: SEgene identifies links between super enhancers and gene expression across cell types
Merged SE region | SE count | Sample count | Gene list |
|---|---|---|---|
chr17: 39,508,684-39,870,304 | 144 | 90 | AC087491.1, STARD3, ERBB2, MIEN1, GRB7, PGAP3, MIR4728 |
chr17: 50,840,427-50,988,719 | 104 | 99 | TOB1 |
chr12: 57,789,943-57,914,845 | 99 | 97 | EEF1AKMT3, LINC02403, TSPAN31, METTL1, CDK4, TSFM, MARCH9, OS9, AC083805.1 |
chr20: 53,461,500-53,949,772 | 97 | 97 | AL354993.2, AC005808.1 |
chr2: 20,411,108-20,648,763 | 93 | 83 | AC023137.1, RHOB |
chr1: 3,060,061-3,439,695 | 89 | 44 | AL008733.1, PRDM16, AL354743.2, AL590438.1, PRDM16-DT |
chr7: 54,397,595-55,219,019 | 77 | 48 | EGFR-AS1, EGFR, SEC61G, ELDR, LANCL2, MRPS17, AC073324.1, CCT6A, AC074351.1, NIPSNAP2, PSPH, CHCHD2 |
chr3: 45,921,160-46,017,087 | 75 | 75 | CXCR6 |
chr2: 87,395,809-87,604,532 | 72 | 72 | CD8A |
chr17: 36,179,756-36,237,793 | 70 | 64 | AC243829.1, CCL3L1 |
chr14: 103,044,456-103,177,781 | 70 | 70 | EXOC3L4 |
chr9: 137,262,240-137,339,439 | 68 | 68 | NRARP |
chr20: 57,646,787-57,857,156 | 67 | 67 | PMEPA1 |
chr20: 23,060,817-23,310,753 | 67 | 67 | CST8 |
chr2: 231,101,775-231,433,680 | 66 | 49 | B3GNT7, ARMC9 |
chr21: 32,402,725-32,537,702 | 66 | 63 | EVA1C |
chr17: 74,370,812-74,530,389 | 63 | 63 | GPRC5C |
chr9: 98,034,579-98,194,184 | 63 | 63 | NANS |
chr5: 1,376,034-1,597,379 | 62 | 60 | LPCAT1, AC091849.2, SLC6A3 |
chr22: 37,448,927-37,596,280 | 61 | 50 | CARD10, LGALS2, TST, BAIAP2L2 |
